• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环肿瘤DNA作为一种癌症生物标志物:生物学特征及可能影响ctDNA分析的因素概述

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis.

作者信息

Sánchez-Herrero Estela, Serna-Blasco Roberto, Robado de Lope Lucia, González-Rumayor Víctor, Romero Atocha, Provencio Mariano

机构信息

Liquid Biopsy Laboratory. Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda, Majadahonda, Spain.

+D Department, Atrys Health, Barcelona, Spain.

出版信息

Front Oncol. 2022 Jul 20;12:943253. doi: 10.3389/fonc.2022.943253. eCollection 2022.

DOI:10.3389/fonc.2022.943253
PMID:35936733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9350013/
Abstract

Cancer cells release nucleic acids, freely or associated with other structures such as vesicles into body fluids, including blood. Among these nucleic acids, circulating tumor DNA (ctDNA) has emerged as a minimally invasive biomarker for tumor molecular profiling. However, certain biological characteristics of ctDNA are still unknown. Here, we provide an overview of the current knowledge about ctDNA biological features, including size and structure as well as the mechanisms of ctDNA shedding and clearance, and the physio-pathological factors that determine ctDNA levels. A better understanding of ctDNA biology is essential for the development of new methods that enable the analysis of ctDNA.

摘要

癌细胞会将核酸释放到包括血液在内的体液中,这些核酸可以是游离状态,也可以与囊泡等其他结构结合。在这些核酸中,循环肿瘤DNA(ctDNA)已成为一种用于肿瘤分子分析的微创生物标志物。然而,ctDNA的某些生物学特性仍不清楚。在此,我们概述了目前关于ctDNA生物学特征的知识,包括其大小和结构、ctDNA释放与清除的机制以及决定ctDNA水平的生理病理因素。更好地理解ctDNA生物学对于开发能够分析ctDNA的新方法至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/a35d2a1ccabc/fonc-12-943253-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/acb4ba76c797/fonc-12-943253-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/826cadac8e5c/fonc-12-943253-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/d41760f91159/fonc-12-943253-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/7e7aa9b19c84/fonc-12-943253-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/a35d2a1ccabc/fonc-12-943253-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/acb4ba76c797/fonc-12-943253-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/826cadac8e5c/fonc-12-943253-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/d41760f91159/fonc-12-943253-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/7e7aa9b19c84/fonc-12-943253-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/367b/9350013/a35d2a1ccabc/fonc-12-943253-g005.jpg

相似文献

1
Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis.循环肿瘤DNA作为一种癌症生物标志物:生物学特征及可能影响ctDNA分析的因素概述
Front Oncol. 2022 Jul 20;12:943253. doi: 10.3389/fonc.2022.943253. eCollection 2022.
2
Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies.循环肿瘤 DNA 和液体活检:检测技术的机遇、挑战和最新进展。
Lab Chip. 2018 Apr 17;18(8):1174-1196. doi: 10.1039/C8LC00100F.
3
ctDNA as a cancer biomarker: A broad overview.ctDNA 作为癌症生物标志物:全面概述。
Crit Rev Oncol Hematol. 2020 Nov;155:103109. doi: 10.1016/j.critrevonc.2020.103109. Epub 2020 Sep 25.
4
[Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].[结直肠癌的液体活检:肿瘤诊断中循环肿瘤DNA分析概述]
Pathologe. 2019 Dec;40(Suppl 3):244-251. doi: 10.1007/s00292-019-00698-3.
5
Trans-Renal Cell-Free Tumor DNA for Urine-Based Liquid Biopsy of Cancer.用于基于尿液的癌症液体活检的经肾无细胞肿瘤DNA
Front Genet. 2022 Apr 27;13:879108. doi: 10.3389/fgene.2022.879108. eCollection 2022.
6
Liquid biopsy of circulating tumor DNA and biosensor applications.循环肿瘤 DNA 的液体活检和生物传感器应用。
Biosens Bioelectron. 2019 Feb 1;126:596-607. doi: 10.1016/j.bios.2018.11.037. Epub 2018 Nov 22.
7
Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.无细胞循环肿瘤核酸,个性化癌症医学的革命。
Crit Rev Oncol Hematol. 2019 Dec;144:102827. doi: 10.1016/j.critrevonc.2019.102827. Epub 2019 Nov 2.
8
The feasibility of using mutation detection in ctDNA to assess tumor dynamics.利用循环肿瘤DNA中的突变检测来评估肿瘤动态变化的可行性。
Int J Cancer. 2017 Jun 15;140(12):2642-2647. doi: 10.1002/ijc.30620. Epub 2017 Mar 2.
9
Circulating Tumor DNA in Pediatric Cancer.小儿癌症中的循环肿瘤DNA
Front Mol Biosci. 2022 May 12;9:885597. doi: 10.3389/fmolb.2022.885597. eCollection 2022.
10
Circulating cell-free tumor DNA analysis in pediatric cancers.循环肿瘤游离 DNA 分析在儿科癌症中的应用。
Mol Aspects Med. 2020 Apr;72:100819. doi: 10.1016/j.mam.2019.09.003. Epub 2019 Sep 25.

引用本文的文献

1
Genomics in Lung Cancer: A Scoping Review of the Role of ctDNA in Non-Advanced Non-Small-Cell Lung Cancer in the Prediction of Prognosis After Multimodality Therapeutic Approaches.肺癌中的基因组学:ctDNA在非晚期非小细胞肺癌多模式治疗后预后预测中作用的范围综述
Genes (Basel). 2025 Aug 15;16(8):962. doi: 10.3390/genes16080962.
2
Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.用于早期癌症检测和诊断的新兴生物标志物:挑战、创新与临床前景
Eur J Med Res. 2025 Aug 18;30(1):760. doi: 10.1186/s40001-025-03003-6.
3
Expanding the use of circulating microbiome in fish: contrast between the gut and blood microbiome of .

本文引用的文献

1
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).新辅助纳武利尤单抗联合化疗治疗可手术 IIIA 期非小细胞肺癌的总生存和生物标志物分析(NADIM Ⅱ期试验)。
J Clin Oncol. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. Epub 2022 May 16.
2
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
3
Circulating tumor DNA and liquid biopsy in oncology.
扩大循环微生物群在鱼类中的应用:[具体鱼类名称]肠道微生物群与血液微生物群的对比
ISME Commun. 2025 Jul 11;5(1):ycaf116. doi: 10.1093/ismeco/ycaf116. eCollection 2025 Jan.
4
From lab to life: technological innovations in transforming cancer metastasis detection and therapy.从实验室到临床:癌症转移检测与治疗变革中的技术创新
Discov Oncol. 2025 Aug 10;16(1):1517. doi: 10.1007/s12672-025-02910-8.
5
Prognostic Significance of the Comprehensive Biomarker Analysis in Colorectal Cancer.综合生物标志物分析在结直肠癌中的预后意义
Life (Basel). 2025 Jul 14;15(7):1100. doi: 10.3390/life15071100.
6
Comparison of level of circulating tumor DNA between oral squamous cell carcinoma and healthy controls: a case control study.口腔鳞状细胞癌与健康对照者循环肿瘤DNA水平的比较:一项病例对照研究。
BMC Oral Health. 2025 Jul 5;25(1):1101. doi: 10.1186/s12903-025-06403-6.
7
Liquid biopsy in breast cancer: clinical implications of ctDNA and CTCs in diagnosis, treatment and monitoring.乳腺癌的液体活检:循环肿瘤DNA和循环肿瘤细胞在诊断、治疗及监测中的临床意义
Mol Cell Biochem. 2025 Jun 30. doi: 10.1007/s11010-025-05343-7.
8
The emerging role of circulating tumor DNA in brain tumor research.循环肿瘤DNA在脑肿瘤研究中的新兴作用。
IBRO Neurosci Rep. 2025 Apr 11;18:714-725. doi: 10.1016/j.ibneur.2025.04.007. eCollection 2025 Jun.
9
Application and recent advances in conventional biomarkers for the prognosis of papillary thyroid carcinoma.传统生物标志物在甲状腺乳头状癌预后评估中的应用及最新进展
Front Oncol. 2025 May 21;15:1598934. doi: 10.3389/fonc.2025.1598934. eCollection 2025.
10
The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection.循环肿瘤细胞、循环肿瘤DNA及其他用于早期癌症检测的新兴生物标志物的开发与应用。
Explor Target Antitumor Ther. 2025 May 13;6:1002314. doi: 10.37349/etat.2025.1002314. eCollection 2025.
循环肿瘤DNA与肿瘤学中的液体活检
Nat Cancer. 2020 Mar;1(3):276-290. doi: 10.1038/s43018-020-0043-5. Epub 2020 Mar 20.
4
Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer.液体活检在非小细胞肺癌患者治疗中的应用。
Curr Treat Options Oncol. 2021 Aug 23;22(10):86. doi: 10.1007/s11864-021-00882-9.
5
Detection of Cell Types Contributing to Cancer From Circulating, Cell-Free Methylated DNA.从循环游离甲基化DNA中检测对癌症有贡献的细胞类型。
Front Genet. 2021 Jul 27;12:671057. doi: 10.3389/fgene.2021.671057. eCollection 2021.
6
Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.检测转移性黑色素瘤患者血浆 ctDNA 以发现临床进展:与影像学进展的比较。
Br J Cancer. 2022 Feb;126(3):401-408. doi: 10.1038/s41416-021-01507-6. Epub 2021 Aug 9.
7
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.TP53 或 DNA 损伤修复基因的突变定义了原发性前列腺癌中预后不良的亚组。
Urol Oncol. 2022 Jan;40(1):8.e11-8.e18. doi: 10.1016/j.urolonc.2021.06.024. Epub 2021 Jul 26.
8
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.液体活检在晚期 NSCLC 中的应用:国际肺癌研究协会的共识声明。
J Thorac Oncol. 2021 Oct;16(10):1647-1662. doi: 10.1016/j.jtho.2021.06.017. Epub 2021 Jul 8.
9
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.利用仅血浆循环肿瘤 DNA 检测在结直肠癌患者中检测微小残留病灶。
Clin Cancer Res. 2021 Oct 15;27(20):5586-5594. doi: 10.1158/1078-0432.CCR-21-0410. Epub 2021 Apr 29.
10
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.分析循环肿瘤DNA以识别可能从序贯酪氨酸激酶抑制剂治疗中获益的表皮生长因子受体阳性非小细胞肺癌患者。
Eur J Cancer. 2021 May;149:61-72. doi: 10.1016/j.ejca.2021.02.031. Epub 2021 Apr 5.